• Publications
  • Influence
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
ContextThe α4β2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel α4β2 nAChR partial agonist, may beExpand
  • 1,155
  • 61
  • PDF
Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
ContextVarenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewardingExpand
  • 1,243
  • 52
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
CONTEXT The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partialExpand
  • 478
  • 52
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
CONTEXT Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing theExpand
  • 436
  • 42
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
CONTEXT The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence. Evidence to support pharmacologicalExpand
  • 609
  • 23
  • PDF
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
Background: Varenicline, a new treatment for smoking cessation, has demonstrated significantly greater efficacy over placebo and sustained release bupropion (bupropion SR). A study was undertaken toExpand
  • 304
  • 23
  • PDF
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
BACKGROUND The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety,Expand
  • 356
  • 22
  • PDF
Efficacy of Varenicline , an 4 2 Nicotinic Acetylcholine Receptor Partial Agonist , vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
CIGARETTE SMOKING REMAINS the leading preventable cause of illness and premature death in the United States, claiming an estimated 438 000 lives per year. Research over the past 3 decades hasExpand
  • 270
  • 19
  • PDF
A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
BACKGROUND Rates of smoking in East Asian men range from >35% to >60%, and are increasing in women and the young. OBJECTIVE This study evaluated the efficacy and tolerability of 1 mg BIDExpand
  • 124
  • 12
Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative
BackgroundThis double-blind, multicenter, placebo-controlled study determined the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR)Expand
  • 381
  • 10